Skip to main content

Enhancing Antibody Development: Leveraging FcRn Transgenic Mice (tg32) for Drug Discovery of Therapeutic Antibodies

Published Date

Presented by Martin Lechmann Ph.D., DMPK/PD Project Lead (DPL) Biologics, Roche Diagnostics GmbH